Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors

• Published in: Journal of cancer epidemiology Vol. 2020; pp. 5615303 - 7
• Main Authors: Barnes, Precious, Yeboah, F. A., Zhu, Jinling, Saahene, Roland Osei, Obirikorang, Christian, Adinortey, Michael Buenor, Amoani, Benjamin, Kyei, Foster, Akakpo, Patrick, Awuku, Yaw Asante
• Format: Journal Article
• Language: English
• Published: Egypt Hindawi 2020; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Age; Analysis; Care and treatment; Epidermal growth factor; Gene expression; Head & neck cancer; Head and neck tumors; Immunohistochemistry; Kinases; Ligands; Medical prognosis; Signal transduction; Teaching hospitals; Tumors; Ghana
• ISSN: 1687-8558; 1687-8566
• DOI: 10.1155/2020/5615303

Introduction. Head and neck tumors (HNT) are tumors that normally occur at the head and neck region of the body. Epidermal growth factor receptor (EGFR) has been found to be highly expressed in breast and other tumors; therefore, there is the need to investigate the level of EGFR expression among patients with head and neck tumors in Ghana. Method. The level of EGFR expression was determined in head and neck tumor and control head and neck tissues with quantitative real-time PCR and immunohistochemistry analysis. Results. The level of EGFR expressions was high in tumor tissues than in the control tissues. There was a significant difference of p value 0.025 among the ages >40 and ≤ 40 when the high and low level of EGFR was compared in the head and neck malignant tumor. The area under the curve for the high expression of EGFR among the malignant head and neck tumors was 0.901 with a specificity of 86.4%. Conclusion. EGFR can serve as a prognostic marker in monitoring patients with HNT as well as a molecular therapeutic target.